Meloxicam

證據等級: L5

預測適應症: 10 個

Meloxicam: From NSAID Use in Osteoarthritis/Rheumatoid Arthritis to Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

One-Sentence Summary

Meloxicam is a COX-2 preferential NSAID established for osteoarthritis and rheumatoid arthritis-type joint inflammation. Among 10 TxGNN-predicted indications for this drug, rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (JIA) is the most clinically defensible candidate — it is mechanistically consistent with meloxicam’s known anti-inflammatory action and already has real-world pediatric use in some markets — supported by 1 observational safety study, though no meloxicam-specific clinical trial currently exists for this exact indication.

Note on candidate selection: This evidence pack contains 10 predicted indications. The single highest TxGNN score (acromesomelic dysplasia, Hunter-Thompson type, 99.92%) is explicitly flagged in its own repurposing rationale as a likely false positive — a structural/developmental skeletal disorder with no inflammatory pathway for an NSAID to act on, most likely reflecting embedding proximity between skeletal/joint disease nodes in the knowledge graph rather than a real signal. Ranks 2, 3, 4, 9 and 10 are similarly unsupported (all L5/Hold). The JIA candidate (rank 8) was selected as the report’s focus because it is the only candidate combining an evidence level above L4, actual literature support, and a documented existing-use precedent.

Quick Overview

Item	Content
Original Indication	NSAID class — osteoarthritis / rheumatoid arthritis (general pharmacological knowledge; no Taiwan license record exists in this evidence pack)
Predicted New Indication	Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (JIA)
TxGNN Prediction Score	99.44%
Evidence Level	L3
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for meloxicam in this evidence pack. Based on known information, meloxicam is a preferential COX-2 inhibitor NSAID; its efficacy in reducing synovial inflammation and joint pain in adult osteoarthritis and rheumatoid arthritis has long been established, and mechanistically this same COX-2-mediated anti-inflammatory pathway may be applicable to juvenile idiopathic arthritis.

Rheumatoid factor-positive polyarticular JIA shares the core pathology of multi-joint synovial inflammation with adult rheumatoid arthritis, meloxicam’s established indication class. Meloxicam has in fact already been approved in some markets for symptomatic treatment of JIA in children aged 2 and older, giving this prediction a real-world use basis beyond the TxGNN score alone.

The supporting literature is a Phase 4 registry cohort study evaluating long-term safety of celecoxib and non-selective NSAIDs (as a drug class, not meloxicam-specific) in JIA patients. This confirms class-level safety in the pediatric JIA population but does not constitute a meloxicam-specific randomized controlled trial, which is why the evidence level is capped at L3 (observational) rather than L1/L2.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25057265	2014	Cohort (Phase 4 registry)	Pediatric Rheumatology Online Journal	Long-term safety and developmental outcomes of celecoxib and non-selective NSAIDs in juvenile idiopathic arthritis patients treated in routine clinical practice

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Meloxicam’s established COX-2-mediated anti-inflammatory mechanism directly addresses the synovial inflammation driving polyarticular JIA, and the drug already has precedent pediatric use for this indication class in some markets. However, evidence is limited to a class-level (not meloxicam-specific) observational safety registry, and this evidence pack shows the drug is not currently marketed or licensed in this jurisdiction, with no TFDA label data available.

To proceed, the following is needed:

TFDA-approved label warnings and contraindications (currently a Blocking data gap — required before any S1 safety screening)
Formal mechanism-of-action documentation from DrugBank or equivalent source
Meloxicam-specific pediatric JIA efficacy/safety data (RCT or prospective cohort), rather than class-level NSAID data
Resolution of local market/licensing status, since the drug currently has zero registered licenses in this market
Drug-drug interaction (DDI) data, currently unavailable (query status: not_found)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.